Acute kidney Injury
Conditions
Interventions
Gold Standard:Determination based on serum creatinine and urine volume according to KDIGO guidelines
AKI was diagnosed as a >= 26.5 umol/L increase in serum creatinine within 48 hours or a >= 50% increase in serum creatinine level from baseline within 7 days. In AKI stage 1, serum creatinine increase
AKI phase 2 refers to an increase in serum creatinine to a baseline value of 2.0-3.0 times
AKI phase 3 is characterized by an increase in serum creatinine to>3.0 times the baseline value, or an increase in serum creatinine to 353.6 µ Mol/L, or start renal replacement therapy.
Index test:Acute renal injury factor TIMP-2/IGFBP-7 detection kit
Urinary tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), Insulin-like growth factor-binding protein 7 (IGFBP7)
Sponsors
Subei People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: a. Male or female over 18 years old b. Subjects are enrolled within 24 hours of admission to the ICU (collection of study samples) c. Expected to remain in the ICU for at least 48 hours after enrollment d. Use an indwelling urinary catheter as a Routine care for at least 48 hours e. At least one of the following acute states was recorded within 24 hours before enrollment: Respiratory system SOFA score = 2 (PaO2/FiO2 < 300); Cardiovascular system SOFA score = 1 (MAP < 70mmHg and/or any vasopressors required).
Exclusion criteria
Exclusion criteria: a. Special populations including pregnant women b. Patients who have received a previous kidney transplant c. Patients who have been diagnosed with KDIGO grade 2/3 AKI d. Patients already on haemodialysis (acute or chronic) or in urgent need of haemodialysis at the time of enrolment e. Patients with HIV infection or active hepatitis (acute or chronic) f. Patients with a history of chronic kidney disease (CKD) but with unknown baseline serum creatinine values (baseline values 6 months prior to enrolment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Human Tissue Inhibitors Of Metalloproteinase 2 (TIMP-2);Insulin Growth Factor Binding Protein 7 (IGFBP7);Sensitivity ;Specificity; | — |
Countries
China
Contacts
Public ContactZheng Ruiqiang
Subei People’s Hospital
Outcome results
None listed